TransMedics Group Inc. Common Stock (TMDX)
Stock · NASDAQ · Health Care
$70.82as of 10/16/2026
Price chart
Active signals
TMDX Signal Track Record
How signals performed across all stocks →What TMDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 35 | +0.3% | 51% | September 11, 2026 |
| Bollinger Band Breakout | 30 | -2.1% | 47% | August 4, 2026 |
| Bollinger Band BreakdownActive now | 18 | -0.9% | 50% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +12.0% | 67% | October 24, 2024 |
| Any 20-session window (baseline) | +3.4% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor org…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 898
- Website
- www.transmedics.com/
Fundamentals
- 1-day range
- $70.03$76.52
- Market cap
- $2.78B
- P/E (trailing)
- 17.33
- P/E (forward)
- 31.40
- EPS (trailing)
- $3.73
- Dividend yield
- —
- Beta
- 2.12
- Avg. volume
- 831.4K
How TransMedics Group Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
TransMedics Group Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TMDXTransMedics Group Inc. Common Stock$70.78▼ 7.50%Market cap $2.78BP/E 17.33$60.11$156
- AXGNAxogen Inc. Common Stock$34.62▼ 2.83%Market cap $2.38BP/E —$15.27$52.91
- CNMDCONMED Corporation Common Stock$46.72▼ 0.89%Market cap $1.49BP/E 25.13$31.44$53.66
- LIVNLivaNova PLC Ordinary Shares$77.58▼ 1.17%Market cap $4.16BP/E 22.41$48.82$85.76
- INMDInMode Ltd. Ordinary Shares$14.16▼ 1.12%Market cap $957.98MP/E 10.66$12.72$16.67
- CBLLCeriBell Inc. Common Stock$25.04▼ 9.41%Market cap $692.45MP/E —$10.85$26.63
- CVCapsoVision Inc. Common Stock$6.53▲ 1.24%Market cap $344.75MP/E —$4.46$15.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TMDX TransMedics Group Inc. Common Stock | $2.78B | 17.33 | $70.78 | ▼ 7.50% | $60.11$156 |
| AXGN Axogen Inc. Common Stock | $2.38B | — | $34.62 | ▼ 2.83% | $15.27$52.91 |
| CNMD CONMED Corporation Common Stock | $1.49B | 25.13 | $46.72 | ▼ 0.89% | $31.44$53.66 |
| LIVN LivaNova PLC Ordinary Shares | $4.16B | 22.41 | $77.58 | ▼ 1.17% | $48.82$85.76 |
| INMD InMode Ltd. Ordinary Shares | $957.98M | 10.66 | $14.16 | ▼ 1.12% | $12.72$16.67 |
| CBLL CeriBell Inc. Common Stock | $692.45M | — | $25.04 | ▼ 9.41% | $10.85$26.63 |
| CV CapsoVision Inc. Common Stock | $344.75M | — | $6.53 | ▲ 1.24% | $4.46$15.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94benzinga · 10/13/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120Benzinga · 10/7/2026
- TransMedics Group (TMDX) Stock Looks Below Fair Value On EarningsYahoo · 10/2/2026
- TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative HoldsYahoo · 10/2/2026
- TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?Yahoo · 9/29/2026
- TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing RisksSeekingAlpha · 9/26/2026
- TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)SeekingAlpha · 9/18/2026
- 2 Stocks Down 28% and 34% to Buy and HoldYahoo · 9/15/2026
Insider Activity
Insider Actions →- Weill David · September 11, 2026 · Buy1.3K @ $81.63
- TOBIN JAMES R · August 17, 2026 · Gift18.0K
- Corcoran Nicholas · July 10, 2026 · Grant17.8K
- Corcoran Nicholas · July 10, 2026 · Grant11.7K
- Hernandez Gerardo · July 10, 2026 · Grant26.2K
- Hernandez Gerardo · July 10, 2026 · Grant17.2K
- Hassanein Waleed H · July 10, 2026 · Grant113.0K
- Hassanein Waleed H · July 10, 2026 · Grant49.7K
- Lovell Stephanie · May 20, 2026 · Grant2.9K
- Weill David · May 20, 2026 · Grant2.9K
- Kania Edwin · May 20, 2026 · Grant2.9K
- Basile Edward M · May 20, 2026 · Grant2.9K
- Gunderson Thomas J. · May 20, 2026 · Grant2.9K
- TOBIN JAMES R · May 20, 2026 · Grant2.9K
- Merilee Raines · May 20, 2026 · Grant2.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 34.58M
- Total value held
- $3.35B
- Institutional holders
- 408
- Unknown5.29M
- Unknown5.10M
- Unknown1.48M
- Unknown1.32M
- Unknown1.04M
- Unknown939.5K
- Unknown885.8K
- Unknown867.2K
- Unknown866.3K
- Unknown839.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
TransMedics Group Faces Analyst Sentiment Shift
Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.
TransMedics Group Faces Analyst Sentiment Shift. Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.